RU2576611C2 - Способы применения производных циклического амида для лечения шизофрении - Google Patents

Способы применения производных циклического амида для лечения шизофрении Download PDF

Info

Publication number
RU2576611C2
RU2576611C2 RU2013107382/15A RU2013107382A RU2576611C2 RU 2576611 C2 RU2576611 C2 RU 2576611C2 RU 2013107382/15 A RU2013107382/15 A RU 2013107382/15A RU 2013107382 A RU2013107382 A RU 2013107382A RU 2576611 C2 RU2576611 C2 RU 2576611C2
Authority
RU
Russia
Prior art keywords
schizophrenia
compound
symptom
sleep
subject
Prior art date
Application number
RU2013107382/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2013107382A (ru
Inventor
Реми Анри ЛУТРИНГЕР
Лоренцо ПЕЛЛЕГРИНИ
Аргерис Н. КАРАБЕЛАС
Original Assignee
Сиренейк Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиренейк Фармасьютикалз, Инк. filed Critical Сиренейк Фармасьютикалз, Инк.
Publication of RU2013107382A publication Critical patent/RU2013107382A/ru
Application granted granted Critical
Publication of RU2576611C2 publication Critical patent/RU2576611C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/0001Arrangements for dividing the transmission path
    • H04L5/0003Two-dimensional division
    • H04L5/0005Time-frequency
    • H04L5/0007Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT
    • H04L5/001Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT the frequencies being arranged in component carriers
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/0001Arrangements for dividing the transmission path
    • H04L5/0014Three-dimensional division
    • H04L5/0016Time-frequency-code
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/0001Arrangements for dividing the transmission path
    • H04L5/0014Three-dimensional division
    • H04L5/0016Time-frequency-code
    • H04L5/0019Time-frequency-code in which one code is applied, as a temporal sequence, to all frequencies
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/003Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048Allocation of pilot signals, i.e. of signals known to the receiver
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/003Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048Allocation of pilot signals, i.e. of signals known to the receiver
    • H04L5/005Allocation of pilot signals, i.e. of signals known to the receiver of common pilots, i.e. pilots destined for multiple users or terminals
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/003Arrangements for allocating sub-channels of the transmission path
    • H04L5/0053Allocation of signalling, i.e. of overhead other than pilot signals
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04WWIRELESS COMMUNICATION NETWORKS
    • H04W4/00Services specially adapted for wireless communication networks; Facilities therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Signal Processing (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2013107382/15A 2010-07-20 2011-07-20 Способы применения производных циклического амида для лечения шизофрении RU2576611C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36607510P 2010-07-20 2010-07-20
US61/366,075 2010-07-20
PCT/US2011/044697 WO2012012542A1 (en) 2010-07-20 2011-07-20 Methods of use of cyclic amide derivatives to treat schizophrenia

Publications (2)

Publication Number Publication Date
RU2013107382A RU2013107382A (ru) 2014-08-27
RU2576611C2 true RU2576611C2 (ru) 2016-03-10

Family

ID=45497166

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013107382/15A RU2576611C2 (ru) 2010-07-20 2011-07-20 Способы применения производных циклического амида для лечения шизофрении

Country Status (22)

Country Link
US (3) US20180155318A1 (enExample)
EP (4) EP4494704A3 (enExample)
JP (2) JP6053678B2 (enExample)
KR (1) KR101867633B1 (enExample)
CN (1) CN103220910B (enExample)
BR (1) BR112013001303A2 (enExample)
CA (2) CA3117855C (enExample)
DK (2) DK3135286T3 (enExample)
ES (2) ES2656313T3 (enExample)
FI (1) FI3135286T3 (enExample)
HR (1) HRP20231446T1 (enExample)
HU (1) HUE064157T2 (enExample)
LT (1) LT3135286T (enExample)
NO (1) NO2595484T3 (enExample)
PL (2) PL3135286T3 (enExample)
PT (2) PT3135286T (enExample)
RS (1) RS64819B1 (enExample)
RU (1) RU2576611C2 (enExample)
SI (1) SI3135286T1 (enExample)
SM (1) SMT202300413T1 (enExample)
TW (1) TWI583679B (enExample)
WO (1) WO2012012542A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2812901C2 (ru) * 2017-06-21 2024-02-05 Минерва Ньюросайенсиз, Инк. Кишечнорастворимые лекарственные формы для перорального применения с контролируемым высвобождением

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058212T2 (hu) * 2014-12-02 2022-07-28 Minerva Neurosciences Inc 2-((1-(2(4-fluorfenil)-2-oxoetil)piperidin-4-il)metil)izoindolin-1-ont tartalmazó készítmények skizofrénia kezelésére
CN113908156A (zh) * 2016-05-25 2022-01-11 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
IL308650B2 (en) 2017-06-21 2025-08-01 Minerva Neurosciences Inc Gastro-resistant controlled release oral dosage forms
MY198713A (en) 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP3840835A1 (en) * 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008152440A (ru) * 2006-05-30 2010-07-10 Элбион Гмбх (De) ПИРИДО[3,2-e]ПИРАЗИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 10 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888340T2 (de) * 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
NZ235841A (en) * 1989-10-27 1993-03-26 Du Pont (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions
CA2069318A1 (en) * 1989-10-27 1991-04-28 Engelbert Ciganek (n-phthalimidoalkyl) piperidines
AU2001234175B2 (en) * 2000-02-29 2004-10-07 Mitsubishi Pharma Corporation Novel cyclic amide derivatives
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
AU2006256583B2 (en) * 2005-06-06 2012-01-12 Merck Sharp & Dohme Limited Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008152440A (ru) * 2006-05-30 2010-07-10 Элбион Гмбх (De) ПИРИДО[3,2-e]ПИРАЗИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 10 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUTHEIL F et al. "Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putatine roles in cerebral function". Drug Metab Dispos 2009 Jul;37(7):1528-38, реферат, найдено 27.04.2015, найдено из PubMed PMID:19359404. YANG C et al. "Clinical significance of sleep EEG abnormalities in chronic schizophrenia". Schizophr Res. 2006 Feb 28;82(2-3):251-60, реферат, найдено 27.04.2015, найдено из PubMed PMID: 16377158. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2812901C2 (ru) * 2017-06-21 2024-02-05 Минерва Ньюросайенсиз, Инк. Кишечнорастворимые лекарственные формы для перорального применения с контролируемым высвобождением

Also Published As

Publication number Publication date
US20180155318A1 (en) 2018-06-07
EP2595484A4 (en) 2014-04-23
US20220274951A1 (en) 2022-09-01
EP3135286B1 (en) 2023-09-06
SI3135286T1 (sl) 2024-02-29
BR112013001303A2 (pt) 2016-05-17
CA3117855C (en) 2023-01-10
RS64819B1 (sr) 2023-12-29
JP2017031159A (ja) 2017-02-09
RU2013107382A (ru) 2014-08-27
SMT202300413T1 (it) 2024-01-10
JP6200561B2 (ja) 2017-09-20
CN103220910A (zh) 2013-07-24
CA2806017A1 (en) 2012-01-26
JP6053678B2 (ja) 2016-12-27
EP4494704A3 (en) 2025-04-23
TWI583679B (zh) 2017-05-21
EP3135286A1 (en) 2017-03-01
EP2595484A1 (en) 2013-05-29
PL2595484T3 (pl) 2018-03-30
PL3135286T3 (pl) 2024-04-22
PT2595484T (pt) 2018-01-22
LT3135286T (lt) 2023-11-10
PT3135286T (pt) 2023-11-28
ES2656313T3 (es) 2018-02-26
TW201211021A (en) 2012-03-16
US20250179044A1 (en) 2025-06-05
HRP20231446T1 (hr) 2024-03-01
NO2595484T3 (enExample) 2018-03-17
KR101867633B1 (ko) 2018-06-15
ES2963362T3 (es) 2024-03-26
CA2806017C (en) 2021-06-29
EP3335731A1 (en) 2018-06-20
WO2012012542A1 (en) 2012-01-26
EP4494704A2 (en) 2025-01-22
JP2013531072A (ja) 2013-08-01
KR20130129905A (ko) 2013-11-29
CN103220910B (zh) 2016-05-11
HUE064157T2 (hu) 2024-02-28
DK2595484T3 (en) 2018-01-22
CA3117855A1 (en) 2012-01-26
FI3135286T3 (fi) 2023-11-15
EP3335731B1 (en) 2024-09-04
EP2595484B1 (en) 2017-10-18
DK3135286T3 (da) 2023-11-27

Similar Documents

Publication Publication Date Title
US9732059B2 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
US20250179044A1 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
JP6419294B2 (ja) シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法
KR20250105660A (ko) 울로타론트를 이용한 신경정신 약물 변경 방법
WO2023243659A1 (ja) 線条体ストリオソームのドパミンd1シグナルを標的とした強迫性障害の薬物療法